We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Read MoreHide Full Article
Key Takeaways
Nuvectis expanded its pipeline with ex-China rights to NXP100 and NXP200 through a Haisco deal.
NXP100 gained China approval for previously untreated PNH patients, strengthening its development outlook.
NXP200 broadens oncology exposure, while NXP900 remains a key catalyst with multiple combination studies.
Shares of Nuvectis Pharma (NVCT - Free Report) have gained approximately 97% over the past three months compared with the industry’s 7.3% growth, fueled by growing investor optimism toward the company’s pipeline and long-term commercial potential. The company is evolving from an early-stage oncology developer into a broader clinical-stage biopharmaceutical company with programs spanning oncology and complement-mediated diseases.
Image Source: Zacks Investment Research
Haisco Deal Marks a Major Pipeline Expansion
A key catalyst came in June, when Nuvectis entered into an agreement with Haisco Pharmaceutical Group to acquire the ex-China rights to a rare-disease candidate NXP100 and an oncology candidate NXP200. The transaction significantly broadened Nuvectis’ pipeline and added two assets with potentially differentiated therapeutic applications.
The deal complemented NXP900, Nuvectis’ internally developed oncology program, with two new candidates that could provide additional near- and long-term value drivers.
NXP100 Adds a Late-Stage Commercial Opportunity
NXP100 is an oral, once-daily complement Factor B inhibitor designed to selectively block the alternative complement pathway. The candidate is being developed for complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy and C3 glomerulonephritis.
In July, NXP100 received approval in China under the brand name Ciprocopan for previously untreated PNH patients who had not previously received complement inhibitors. The approval provides clinical and regulatory validation of the drug’s mechanism and positions the company to advance NXP100 toward later-stage development and eventual commercialization in ex-China markets, creating a clearer path to value creation.
NXP200, the second asset acquired from Haisco, further strengthens Nuvectis’ oncology portfolio. NXP200 is an oral paradox breaker BRAF inhibitor targeting class I, II and III BRAF mutations. Unlike conventional BRAF inhibitors, NXP200 is designed to inhibit BRAF signaling while avoiding paradoxical activation associated with earlier-generation approaches. The program is being evaluated in oncology, including BRAF-mutant glioma and Nuvectis has presented preclinical research supporting its potential.
The strategic importance of NXP200 is that it gives the company another differentiated oncology asset along with NXP900. This could reduce the company’s reliance on a single oncology candidate and increase the potential value of its overall pipeline. U.S. regulatory activities for NXP200 are progressing, with the investigational new drug application filing anticipated in the fourth quarter of 2026.
NXP900 Remains an Important Catalyst
NXP900 is an oral SRC/YES1 kinase inhibitor with a differentiated Type 1.5 mechanism designed to inhibit both the catalytic and scaffolding functions of SRC-family kinases. NXP900 is being advanced in combination studies across non-small cell lung cancer (NSCLC) and pancreatic cancer. In NSCLC, data from the ongoing NXP900 plus osimertinib study is expected by year-end 2026, while a study combining NXP900 with lorlatinib in ALK-positive patients is expected to begin in the third quarter of 2026. In pancreatic cancer, an investigator-sponsored study evaluating NXP900 with daraxonrasib is planned at two U.S. medical centers, subject to FDA approval and drug availability.
NVCT’s Zacks Rank & Stocks to Consider
Nuvectis currently carries a Zacks Rank #3 (Hold).
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 44.4% year to date.
Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 61.5% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 18.2% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
View the Zacks #1 Rank List
Image: Bigstock
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Key Takeaways
Shares of Nuvectis Pharma (NVCT - Free Report) have gained approximately 97% over the past three months compared with the industry’s 7.3% growth, fueled by growing investor optimism toward the company’s pipeline and long-term commercial potential. The company is evolving from an early-stage oncology developer into a broader clinical-stage biopharmaceutical company with programs spanning oncology and complement-mediated diseases.
Image Source: Zacks Investment Research
Haisco Deal Marks a Major Pipeline Expansion
A key catalyst came in June, when Nuvectis entered into an agreement with Haisco Pharmaceutical Group to acquire the ex-China rights to a rare-disease candidate NXP100 and an oncology candidate NXP200. The transaction significantly broadened Nuvectis’ pipeline and added two assets with potentially differentiated therapeutic applications.
The deal complemented NXP900, Nuvectis’ internally developed oncology program, with two new candidates that could provide additional near- and long-term value drivers.
NXP100 Adds a Late-Stage Commercial Opportunity
NXP100 is an oral, once-daily complement Factor B inhibitor designed to selectively block the alternative complement pathway. The candidate is being developed for complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy and C3 glomerulonephritis.
In July, NXP100 received approval in China under the brand name Ciprocopan for previously untreated PNH patients who had not previously received complement inhibitors. The approval provides clinical and regulatory validation of the drug’s mechanism and positions the company to advance NXP100 toward later-stage development and eventual commercialization in ex-China markets, creating a clearer path to value creation.
Nuvectis Pharma, Inc. Price and Consensus
Nuvectis Pharma, Inc. price-consensus-chart | Nuvectis Pharma, Inc. Quote
NXP200 Broadens the Oncology Opportunity
NXP200, the second asset acquired from Haisco, further strengthens Nuvectis’ oncology portfolio. NXP200 is an oral paradox breaker BRAF inhibitor targeting class I, II and III BRAF mutations. Unlike conventional BRAF inhibitors, NXP200 is designed to inhibit BRAF signaling while avoiding paradoxical activation associated with earlier-generation approaches. The program is being evaluated in oncology, including BRAF-mutant glioma and Nuvectis has presented preclinical research supporting its potential.
The strategic importance of NXP200 is that it gives the company another differentiated oncology asset along with NXP900. This could reduce the company’s reliance on a single oncology candidate and increase the potential value of its overall pipeline. U.S. regulatory activities for NXP200 are progressing, with the investigational new drug application filing anticipated in the fourth quarter of 2026.
NXP900 Remains an Important Catalyst
NXP900 is an oral SRC/YES1 kinase inhibitor with a differentiated Type 1.5 mechanism designed to inhibit both the catalytic and scaffolding functions of SRC-family kinases. NXP900 is being advanced in combination studies across non-small cell lung cancer (NSCLC) and pancreatic cancer. In NSCLC, data from the ongoing NXP900 plus osimertinib study is expected by year-end 2026, while a study combining NXP900 with lorlatinib in ALK-positive patients is expected to begin in the third quarter of 2026. In pancreatic cancer, an investigator-sponsored study evaluating NXP900 with daraxonrasib is planned at two U.S. medical centers, subject to FDA approval and drug availability.
NVCT’s Zacks Rank & Stocks to Consider
Nuvectis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) and Precigen (PGEN - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each, while AC Immune (ACIU - Free Report) carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 44.4% year to date.
Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 61.5% year to date.
Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.
Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 18.2% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.